What alternative insomnia treatments are appropriate for a 36‑year‑old man on buprenorphine/naloxone (Suboxone) 2 mg who has chronic insomnia despite trials of trazodone, doxepin, mirtazapine, zolpidem (Ambien), suvorexant (Belsomra), lemborexant (Quviviq), hydroxyzine, quetiapine, clonidine, low‑dose lorazepam, and ramelteon, with only temazepam 30 mg effective, and is prescribing zolpidem at 20 mg safe?

Refractory Insomnia in a Patient on Suboxone: Next Steps

Given that temazepam 30 mg is the only effective agent and you have exhausted guideline-recommended first-line options, you should prescribe temazepam 15 mg (the evidence-based dose) rather than escalating zolpidem to 20 mg, which exceeds FDA-approved dosing and lacks safety data. 1

Why Temazepam is the Appropriate Choice

• The AASM 2017 guideline explicitly recommends temazepam for both sleep-onset and sleep-maintenance insomnia based on trials using 15 mg doses, not 30 mg. 1 Your patient is receiving double the evidence-based dose, which increases risk without additional proven benefit.

• Temazepam 15 mg is a guideline-supported benzodiazepine receptor agonist with demonstrated efficacy for this exact clinical scenario—refractory insomnia after failure of multiple non-benzodiazepine agents. 1, 2

• In patients on buprenorphine with severe insomnia, the prevalence of clinically significant sleep disturbance approaches 60%, and untreated insomnia is associated with worse OUD treatment outcomes, increased negative emotionality, and higher relapse risk. 3 The harm of undertreating his insomnia (potential return to street drugs and hospitalization) outweighs the theoretical risks of long-term benzodiazepine use when properly monitored.

Why Zolpidem 20 mg is NOT Appropriate

• The FDA-approved maximum dose of zolpidem is 10 mg for adults; the AASM guideline recommendation is based exclusively on 10 mg trials. 1 There is no published evidence supporting efficacy or safety at 20 mg.

• The FDA has issued explicit warnings about complex sleep behaviors (sleep-driving, sleepwalking) with zolpidem, and these risks are dose-dependent. 2 Doubling the approved dose in a patient with substance use history creates unacceptable safety concerns.

• Zolpidem already failed at the standard 10 mg dose in your patient, so escalating to a supratherapeutic dose is not evidence-based and violates prescribing standards.

Optimizing the Temazepam Regimen

• Reduce the temazepam dose from 30 mg to 15 mg (the guideline-recommended dose) to minimize adverse effects while maintaining efficacy. 1 If sleep deteriorates at 15 mg, you can titrate back to 22.5 mg (splitting the difference) rather than continuing 30 mg indefinitely.

• Combine temazepam 15 mg with low-dose doxepin 3–6 mg to target sleep maintenance specifically, which may allow further reduction of the benzodiazepine dose over time. 2 The AASM explicitly recommends this combination strategy for refractory cases. 2

• Ensure you previously used doxepin at the correct FDA-approved insomnia doses (3 mg or 6 mg), not higher antidepressant doses. 2 At 3–6 mg, doxepin selectively blocks H1 receptors for sleep maintenance without anticholinergic effects; higher doses lose this selectivity and are not recommended for insomnia. 2

Addressing Your Reluctance to Prescribe Benzodiazepines

• The AASM guideline acknowledges that benzodiazepines are appropriate when first-line agents fail, particularly in patients unable to access CBT-I. 1 Your patient has exhausted all recommended alternatives (BzRAs, orexin antagonists, ramelteon, low-dose doxepin).

• The risk-benefit calculation shifts dramatically in a patient with documented history of hospitalization from street drug use due to untreated insomnia. 3 Controlled prescription of temazepam under close monitoring is safer than the alternative of uncontrolled substance use.

• Implement a structured monitoring plan: monthly visits initially, urine drug screening to confirm absence of illicit substances, pill counts, and a written treatment agreement specifying that temazepam will be discontinued if he uses non-prescribed sedatives. This transforms benzodiazepine prescribing from "risky" to "appropriately managed."

Why Your Previously Tried Agents Failed

• Trazodone is explicitly NOT recommended by the AASM due to lack of efficacy (sleep efficiency improved only 1.38% vs. placebo, 95% CI -2.87 to 5.63) and significant side effects. 1, 2 It should not have been tried.

• Quetiapine at any dose is classified by the AASM as "other sedating agents" reserved for specific comorbidities, not primary insomnia, and carries risks of metabolic syndrome, falls, and mortality in older adults. 2 Its use was not guideline-concordant.

• Mirtazapine is not listed as a recommended treatment in the AASM 2017 guideline, indicating insufficient evidence for primary insomnia. 2

• Lorazepam 2 mg is not a guideline-recommended benzodiazepine for insomnia; the AASM specifically recommends triazolam 0.25 mg or temazepam 15 mg. 1 Lorazepam has a longer half-life and greater next-day impairment, which may explain why it was ineffective or poorly tolerated.

Alternative Strategies if You Absolutely Refuse Temazepam

• Retry lemborexant (Quviviq) at the correct dose: The FDA-approved dose is 5 mg or 10 mg, and network meta-analyses show lemborexant 10 mg has the highest probability of being the most effective treatment for objectively measured total sleep time and latency to persistent sleep. 4, 5 If you tried a lower dose previously, escalate to 10 mg.

• Retry suvorexant (Belsomra) at 20 mg (the maximum dose for adults under 65). 6 The AASM recommendation is based on 10 mg, 15/20 mg, and 20 mg trials, and higher doses show dose-dependent efficacy for sleep maintenance. 1, 6 Suvorexant 20 mg may succeed where lower doses failed.

• Add ramelteon 8 mg to an existing regimen: Ramelteon targets sleep onset and has no abuse potential, no withdrawal, and can be safely combined with other agents. 2, 7 Consider ramelteon 8 mg + doxepin 6 mg as a combination strategy. 2, 7

Critical Safety Warnings for Orexin Antagonists

• Both lemborexant and suvorexant carry FDA warnings about CNS depression, complex sleep behaviors, sleep paralysis, hypnagogic hallucinations, and cataplexy-like symptoms (sudden leg weakness). 8, 6 These risks are dose-dependent and may be higher in patients on buprenorphine due to additive CNS effects.

• The FDA explicitly warns against combining orexin antagonists with alcohol or other CNS depressants, which includes buprenorphine. 8 While not contraindicated, this requires careful counseling and monitoring.

What You Should NOT Do

• Do not prescribe zolpidem 20 mg—this is off-label, lacks evidence, and violates FDA dosing guidelines. 1

• Do not retry trazodone, quetiapine, or mirtazapine—these are not guideline-recommended for primary insomnia and have already failed. 1, 2

• Do not use diphenhydramine or other over-the-counter antihistamines—the AASM explicitly recommends against these due to anticholinergic effects and lack of efficacy. 2

• Do not continue temazepam 30 mg indefinitely without attempting dose reduction—the evidence supports 15 mg, and you should optimize to the lowest effective dose. 1

Practical Algorithm for This Patient

1. Reduce temazepam to 15 mg nightly and monitor for 2 weeks. 1
2. If sleep deteriorates, add doxepin 3 mg (can escalate to 6 mg if needed) to target sleep maintenance. 2
3. If the combination is insufficient, increase temazepam to 22.5 mg (not back to 30 mg) while continuing doxepin 6 mg. 1, 2
4. If you refuse benzodiazepines entirely, retry lemborexant 10 mg or suvorexant 20 mg as monotherapy, with explicit counseling about CNS depression risks on buprenorphine. 8, 6, 4, 5
5. Implement monthly monitoring: assess for daytime sedation, falls, cognitive impairment, and illicit substance use via urine drug screen. 3
6. Counsel the patient that improved sleep is critical to his OUD recovery and that controlled prescription of temazepam is safer than the alternative of street drug use. 3